Honor recognizes his advances in predicting in vivo drug responses based on in vitro data ST. LOUIS, MO – Feb. 26, 2014 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that Amin Rostami, Pharm.D., Ph.D., FCP, the company’s vice … Continued
Month: February 2014
Area under the curve or AUC is a pharmacokinetic statistic used to describe the total exposure to a drug. More specifically, it is the time-averaged concentration of drug circulating in the body fluid analyzed (normally plasma, blood or serum). Standard calculation of AUC involves using non-compartmental techniques to calculate the AUC from time 0 to … Continued
Data published in Pain and Therapy compare tramadol with tapentadol ST. LOUIS, MO – Feb. 24, 2014 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced today that its model-based meta-analysis comparing tramadol with tapentadol for the treatment of chronic nonmalignant … Continued
Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 approved for second line treatment of advanced renal cell carcinoma. The objectives of this analysis were to assess plasma pharmacokinetics and identify covariates that may explain variability in axitinib disposition following single dose administration in healthy … Continued
In this webinar, David Lowis, D. Phil. of Certara, makes the case for adopting a solution that allows immediate access, visualization and analysis of pre-clinical data for optimized decision making, while leveraging the FDA mandated CDISC-SEND data standard. Joining Dr. Lowis will be Stuart Horowitz, PhD, President of Institutional Services at WIRB-Copernicus Group. Dr. Horowitz … Continued
Pain is a major symptom in many medical conditions which can be relieved thanks to analgesics. The goal of this work was to present an indirect comparison of efficacy and tolerability profiles of two analgesics, tramadol and tapentadol, in patients with chronic non-malignant pain.